Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors

Biochemical and Biophysical Research Communications

Volumn 404, Issue 1, 2011, Pages 68-73

  Song, Hui ^a,b   Li, Chia Wei ^a   Labaff, Adam M ^a,b   Lim, Seung Oe ^a   Li, Long Yuan ^c,d,e   Kan, Shu Fen ^c   Chen, Yue ^f   Zhang, Kai ^f   Lang, Jingyu ^a   Xie, Xiaoming ^a   Wang, Yan ^a   Huo, Long Fei ^a   Hsu, Sheng Chieh ^a   Chen, Xiaomin ^a   Zhao, Yingming ^f   Hung, Mien Chie ^a,b,c,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acetylation; CBP; EGFR; Phosphorylation; SAHA

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; TYROSINE; VORINOSTAT;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

EID: 78650905900     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.064     Document Type: Article

References (29)

1. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
2. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7:505-516.
3. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
4. Huang F., Kirkpatrick D., Jiang X., Gygi S., Sorkin A. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol. Cell 2006, 21:737-748.
5. Oved S., Mosesson Y., Zwang Y., Santonico E., Shtiegman K., Marmor M.D., Kochupurakkal B.S., Katz M., Lavi S., Cesareni G., Yarden Y. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J. Biol. Chem. 2006, 281:21640-21651.
6. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277:46265-46272.
7. Zhang X., Gureasko J., Shen K., Cole P.A., Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137-1149.
8. Poppleton H.M., Wiepz G.J., Bertics P.J., Patel T.B. Modulation of the protein tyrosine kinase activity and autophosphorylation of the epidermal growth factor receptor by its juxtamembrane region. Arch. Biochem. Biophys. 1999, 363:227-236.
9. Yang X.J., Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007, 26:5310-5318.
10. Jensen O.N. Interpreting the protein language using proteomics. Nat. Rev. Mol. Cell Biol. 2006, 7:391-403.
11. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26:1351-1356.
12. Pulukuri S.M., Gorantla B., Rao J.S. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator (uPA). J. Biol. Chem. 2007, 282:35594-35603.
13. Munshi A., Kurland J.F., Nishikawa T., Tanaka T., Hobbs M.L., Tucker S.L., Ismail S., Stevens C., Meyn R.E. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 2005, 11:4912-4922.
14. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 2007, 74:659-671.
15. Kelly W.K., Marks P.A. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2005, 2:150-157.
16. Chinnaiyan P., Allen G.W., Harari P.M. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin. Radiat. Oncol. 2006, 16:59-64.
17. Edwards A., Li J., Atadja P., Bhalla K., Haura E.B. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol. Cancer Ther. 2007, 6:2515-2524.
18. Zhou C., Qiu L., Sun Y., Healey S., Wanebo H., Kouttab N., Di W., Yan B., Wan Y. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int. J. Oncol. 2006, 29:269-278.
19. Goh L.K., Huang F., Kim W., Gygi S., Sorkin A. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J. Cell Biol. 2010, 189:871-883.
20. Gao Y.S., Hubbert C.C., Yao T.P. The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J. Biol. Chem. 2010, 285:11219-11226.
21. Deribe Y.L., Wild P., Chandrashaker A., Curak J., Schmidt M.H., Kalaidzidis Y., Milutinovic N., Kratchmarova I., Buerkle L., Fetchko M.J., Schmidt P., Kittanakom S., Brown K.R., Jurisica I., Blagoev B., Zerial M., Stagljar I., Dikic I. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci. Signal 2009, 2:84.
22. Kamemura K., Ito A., Shimazu T., Matsuyama A., Maeda S., Yao T.P., Horinouchi S., Khochbin S., Yoshida M. Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells. Biochem. Biophys. Res. Commun. 2008, 374:84-89.
23. Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.J., Zhao Y. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 2006, 23:607-618.
24. Tang X., Gao J.S., Guan Y.J., McLane K.E., Yuan Z.L., Ramratnam B., Chin Y.E. Acetylation-dependent signal transduction for type I interferon receptor. Cell 2007, 131:93-105.
25. Yamasaki F., Zhang D., Bartholomeusz C., Sudo T., Hortobagyi G.N., Kurisu K., Ueno N.T. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol. Cancer Ther. 2007, 6:2168-2177.
26. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., Wong K.K., Brandstetter K., Wittner B., Ramaswamy S., Classon M., Settleman J. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
27. Munshi N., Agalioti T., Lomvardas S., Merika M., Chen G., Thanos D. Coordination of a transcriptional switch by HMGI(Y) acetylation. Science 2001, 293:1133-1136.
28. Cohen H.Y., Lavu S., Bitterman K.J., Hekking B., Imahiyerobo T.A., Miller C., Frye R., Ploegh H., Kessler B.M., Sinclair D.A. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 2004, 13:627-638.
29. Cohen T., Yao T.P. AcK-knowledge reversible acetylation. Sci. STKE 2004, 245:42.